Vest Financial LLC Has $72.41 Million Position in AbbVie Inc. $ABBV

Vest Financial LLC lowered its stake in AbbVie Inc. (NYSE:ABBV) by 2.9% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 312,742 shares of the company’s stock after selling 9,478 shares during the period. AbbVie makes up approximately 0.9% of Vest Financial LLC’s holdings, making the stock its 13th biggest position. Vest Financial LLC’s holdings in AbbVie were worth $72,412,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of ABBV. Evolution Wealth Management Inc. bought a new position in AbbVie in the 2nd quarter worth approximately $26,000. Spurstone Advisory Services LLC bought a new stake in AbbVie in the second quarter valued at about $28,000. Financial Gravity Companies Inc. acquired a new position in AbbVie in the second quarter worth about $36,000. Delos Wealth Advisors LLC acquired a new stake in shares of AbbVie during the second quarter worth approximately $39,000. Finally, Bear Mountain Capital Inc. raised its position in AbbVie by 480.6% in the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock valued at $40,000 after purchasing an additional 173 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

Analyst Upgrades and Downgrades

ABBV has been the subject of a number of research reports. Citigroup lowered their price target on shares of AbbVie from $240.00 to $235.00 and set a “neutral” rating for the company in a report on Monday, November 3rd. Bank of America raised their price objective on shares of AbbVie from $220.00 to $251.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. UBS Group reaffirmed a “neutral” rating on shares of AbbVie in a research note on Tuesday, January 13th. HSBC upgraded AbbVie from a “hold” rating to a “buy” rating and boosted their target price for the stock from $225.00 to $265.00 in a research report on Wednesday, December 10th. Finally, Guggenheim boosted their target price on AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a research note on Monday, October 20th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $248.11.

AbbVie Stock Performance

ABBV opened at $213.90 on Wednesday. The firm has a market cap of $378.04 billion, a P/E ratio of 162.05, a price-to-earnings-growth ratio of 0.88 and a beta of 0.36. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The business’s fifty day moving average is $226.50 and its 200-day moving average is $216.99.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The business had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. During the same quarter in the previous year, the firm earned $3.00 earnings per share. AbbVie’s revenue for the quarter was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, research analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, January 16th. This is a boost from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.2%. AbbVie’s payout ratio is presently 524.24%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.